

DAFTAR PUSTAKA

1. **Sozzi G**, Oggionni M, Alasio L, *et al.* Molecular changes track recurrence and progression of bronchial precancerous lesions. *Lung Cancer* 2018;**37**:267–70.
[\[PubMed\]](#)
2. **Boers JE**, Velde GP Mt, Thunnissen FBJM. P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. *Am Rev Respir Dis* 2020;**153**:411–16.
3. **Martin B**, Verdebout JM, Mascaux C, *et al.* Expression of p53 in preneoplastic and early neoplastic bronchial lesions. *Oncol Rep* 2019;**9**:223–9.
4. **Bota S**, Auliac JB, Paris C, *et al.* Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. *Am J Respir Crit Care Med* 2019;**164**:1688–93.
5. **Risse EK**, van't Hof MA, Vooijs GP. Relationship between patient characteristics and the sputum cytologic diagnosis of lung cancer. *Acta Cytol* 2017;**31**:159–65.
6. **Bechtel JJ**, Kelley WR, Petty TL, *et al.* Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program. *Arch Intern Med* 2018;**154**:975–80.
7. **Strauss GM**, Gleason RE, Sugarbaker DJ. Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening. *Chest* 2020;**107**:270S–9S.
8. **Greenberg SD**, Hunter NR, Taylor GR, *et al.* Application of cell-image analysis to the diagnosis of cellular atypias in sputum: a review. *Diagn Cytopathol* 2017;**2**:168–74.

9. **Palcic B**, Garner DM, Beveridge J, *et al.* Increase of sensitivity of sputum cytology using high-resolution image cytometry: field study results. *Cytometry* 2020;**50**:168–76.
10. **Tockman MS**, Erozan YS, Gupta P, *et al.* The early detection of second primary lung cancers by sputum immunostaining. LCEWDG investigators. Lung cancer early detection group. *Chest* 2019;**106**:385S–390S.
11. **Sueoka E**, Sueoka N, Goto Y, *et al.* Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. *Cancer Res* 2021
12. **Mao L**, Hruban RH, Boyle JO, *et al.* Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. *Cancer Res* 2021;**54**:1634–7.
13. **Nakajima E**, Hirano T, Konaka C, *et al.* K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. *Int J Oncol* 2020;**18**:105–10.
14. **Kersting M**, Friedl C, Kraus A, *et al.* Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. *J Clin Oncol* 2019;**18**:3221–9.
15. **Somers VA**, Thunnissen FB. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. *Methods Mol Med* 2019;**75**:305–23.
16. I Gusti Bagus Mulia Agung Pradnyaandara, Herman Saputra, I Gusti Ayu Sri Mahendra Dewi, I Wayan Juli Sumadi, [KARAKTERISTIK PASIEN KARSINOMA PARU DI RSUP SANGLAH DENPASAR TAHUN 2017-2018](#), [E-](#)

17. Putu Dony Astika Wiguna, Herman Saputra, I Gusti Ayu Sri Mahendra Dewi, [DIAGNOSIS SITOLOGI PASIEN DENGAN DIAGNOSIS KLINIS TUMOR PARU BERDASARKAN BERBAGAI METODE PENGAMBILAN SAMPEL SITOLOGI DI RSUP SANGLAH TAHUN 2014-2018](#), [E-Jurnal Medika Udayana: Vol 10 No 11 \(2021\): Vol 10 No 11\(2021\): E-Jurnal Medika Udayana](#)
18. Wiwien HW, Anwar J, Muhammad YHP. Akurasi pemeriksaan sitologi dan histopatologi pada pasien kanker paru di beberapa rumah sakit Jakarta tahun 2000 – 2005. *Jurnal Respirologi Indonesia* 2007; 27: 219-25
19. Kennedy TC, Miller Y, Prindiville S. Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high risk group. *Chest* 2000; 17(Suppl): 72-9.
20. . Chodosh S. Sputum examination. In: Fishman AP, editor. *Pulmonary diseases and disorders*. Philadelphia: Mc Grow Hill Book Company; 1988.p.411-26
21. Horn L, Lovly CM. Neoplasms of the Lung. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editors. *Harrison's Principles of Internal Medicine*: McGraw Hill; 2018.
22. Gouvinhas C, Mello RAD, Oliveira D, Castro-Lopes JM, Castelo-Branco P, Santos RSd, et al. Lung cancer: a brief review of epidemiology and screening. *Future Oncology*. 2018;14(6):567-75.
23. Purnamawati CT, Sumbayak EM, Kertadjaya W. Analisis Kejadian Kanker Paru Primer di Indonesia pada Tahun 2014-2019. 2021.

24. Ahmed HG, Abboh EAA, Alnajib AMA. Is sputum cytology reliable for detection of atypical lung epithelial proliferative changes triggered by cigarette smoking? *International journal of clinical and experimental pathology*. 2021;14(5):618.
25. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. *Annals of global health*. 2019;85(1).
26. Spiro SG, Shah PL, Rintoul RC, George J, Janes S, Callister M, et al. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group. *European Respiratory Journal*. 2019;54(4).
27. Jain D, Roy-Chowdhuri S. Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review. *Archives of Pathology & Laboratory Medicine*. 2018;142(9):1127-33.
28. Eldridge L. Procedure and Results of Sputum Cytology 2020 [updated 22 November 2020. Available from: <https://www.verywellhealth.com/sputum-cytology-2249193>.
29. Chowdhury MM, Arif MH, Ullah EE, Al Mamun A, Karim MN, Biswas R. A Prospective Observational Study between the Value of Sputum Cytology and FNAC of Bronchial Growth in Diagnosing Lung Cancer at Chattogram Medical College Hospital, Bangladesh. *Asian Journal of Medical Sciences*. 2021;12(9):55-9.
30. Fan Y, Su Z, Wei M, Liang H, Jiang Y, Li X, et al. Long-term lung cancer risk associated with sputum atypia: a 27-year follow-up study of an occupational lung screening cohort in Yunnan, China. *Cancer Epidemiology and Prevention Biomarkers*. 2021;30(11):2122-9.

31. Fukui M, Suzuki K, Matsunaga T, Oh S, Takamochi K. Importance of Smoking Cessation on Surgical Outcome in Primary Lung Cancer. *The Annals of Thoracic Surgery*. 2019;107(4):1005-9.
32. Erozan YS, Ramzy I. Primary Epithelial Malignancies. *Pulmonary Cytopathology*: Springer; 2014. p. 115-80.
33. Amy R. Diagnostic Lung Cytology 2016 [Available from: <https://thoracickey.com/diagnostic-lung-cytology/>].
34. Ammanagi A, Dombale V, Miskin A, Dandagi G, Sangolli S. Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man's bronchoscopy!). *Lung India : official organ of Indian Chest Society*. 2012;29:19-23.
35. Felten MK, Knoll L, Schikowsky C, Das M, Feldhaus C, Hering KG, et al. Is it useful to combine sputum cytology and low-dose spiral computed tomography for early detection of lung cancer in formerly asbestos-exposed power industry workers? *Journal of Occupational Medicine and Toxicology*. 2014;9(1):14.
36. Mur LA, Huws SA, Cameron SJ, Lewis PD, Lewis KE. Lung cancer: a new frontier for microbiome research and clinical translation. *Ecancermedicalscience*. 2018;12.
37. Chowdhury MM, Arif MH, Ekram Ullah E, Al Mamun A, Karim MN, Biswas R. A Prospective Observational Study between the Value of Sputum Cytology and FNAC of Bronchial Growth in Diagnosing Lung Cancer at Chattogram Medical College Hospital, Bangladesh. *Asian Journal of Medical Sciences*. 2021;12(9):55-9.

38. Morikawa K, Kinoshita K, Kida H, Inoue T, Mineshita M. Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs. *Genes*. 2022;13(5):812.
39. Shen F, Sergi C. Sputum analysis. 2020.
40. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. *Cochrane Database of Systematic Reviews*. 2017(8).
41. Gupta C, Su J, Zhan M, Stass SA, Jiang F. Sputum long non-coding RNA biomarkers for diagnosis of lung cancer. *Cancer Biomarkers*. 2019;26:219-27.